HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy: Difference between revisions

[pending revision][pending revision]
Line 140: Line 140:
|Gain
|Gain
|Chr21
|Chr21
|<span class="blue-text">EXAMPLE:</span>
|''RUNX1''
Unknown
|<span class="blue-text">EXAMPLE:</span> D, P
|<span class="blue-text">EXAMPLE:</span> D, P
|<span class="blue-text">EXAMPLE:</span> No
|<span class="blue-text">EXAMPLE:</span> No
Line 147: Line 146:
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|X
8
|Gain
|<span class="blue-text">EXAMPLE:</span> Gain
|ChrX
|<span class="blue-text">EXAMPLE:</span>
chr8
|<span class="blue-text">EXAMPLE:</span>
|<span class="blue-text">EXAMPLE:</span>
Unknown
Unknown
Line 159: Line 156:
Common recurrent secondary finding for t(8;21) (add references).
Common recurrent secondary finding for t(8;21) (add references).
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|6
17
|Gain
|<span class="blue-text">EXAMPLE:</span> Amp
|Chr6
|<span class="blue-text">EXAMPLE:</span>
17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
|<span class="blue-text">EXAMPLE:</span>
|<span class="blue-text">EXAMPLE:</span>
''ERBB2''
''ERBB2''
Line 171: Line 166:
Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
|-
|-
|14
|Gain
|Chr14
|
|
|
|
|-
|18
|Gain
|Chr18
|
|
|Prognostic significance: has been correlated with a lower risk of relapse
|
|
|
|
|-
|4
|Gain
|Chr4
|
|
|
|
|-
|17
|Gain
|Chr17
|
|
|
|
|-
|10
|Gain
|Chr10
|
|
|
|
|-
|8
|Gain
|Chr8
|
|
|
|